SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ORZEYFUL

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Approved but awaiting DEA scheduling before US dispensing (expected by November 2026); already launched in Japan and China (October 2026).
Why 4/10
Orzeyful is already FDA-approved (August 5, 2026) with no pending PDUFA or pivotal readout; the remaining near-term catalyst is the DEA scheduling decision expected by November 2026, a procedural step rather than a binary regulatory event. For a large diversified pharma like Takeda, this single drug drives limited share-price impact, scoring 4.
Actionable Insight NEUTRAL

Watch for the DEA scheduling decision expected by November 2026, which will determine when Orzeyful can be dispensed in the US. Also watch Takeda's December 11, 2026 Capital Markets Day for peak-sales targets and Q3 brand growth. The stock is down ~1.9% today at $19.77 as of this report.

Price Chart

Loading chart...

Executive Summary

Orzeyful (oveporexton, formerly TAK-861) is Takeda's first-in-class oral orexin receptor 2 (OX2R) agonist approved by the FDA on August 5, 2026 for narcolepsy type 1 in adults. It is the first drug to treat the underlying orexin deficiency rather than just symptoms. Two Phase 3 trials (FirstLight and RadiantLight) met all endpoints. The drug is also approved in China (July 2026) and Japan (October 2026), with launches underway in Japan and China. US commercial launch awaits DEA scheduling, expected by November 2026. Analysts project $2-3 billion peak sales for NT1 alone. For Takeda, a large diversified pharma, Orzeyful is one of many pipeline assets, limiting its single-drug impact on the stock.

How It Works

Orzeyful is an oral tablet that acts like a key to activate orexin receptors in the brain. Orexin is a natural chemical that promotes wakefulness; people with narcolepsy type 1 have lost the cells that produce orexin. By directly stimulating the orexin receptor, Orzeyful restores the brain's wake-up signal, addressing the root cause of the disease rather than just treating individual symptoms like sleepiness or muscle weakness.

Trial Status

Two Phase 3 trials (FirstLight NCT06470828 and RadiantLight NCT06505031) completed with all primary and secondary endpoints met. FDA approved August 5, 2026. Also approved in China July 2026 and Japan October 2026.

The Two-Sided Case

▲ Bull Case6
First-in-class oral orexin receptor 2 (OX2R) agonist, the first drug to treat the underlying orexin deficiency causing narcolepsy type 1 rather than just symptoms.
Met all primary and secondary endpoints in two pivotal Phase 3 trials (FirstLight and RadiantLight), showing statistically significant improvements in wakefulness and daily functioning.
Approved in the US (August 5, 2026), China (July 2026), and Japan (October 2026), with launches underway in Japan and China.
Analysts project peak sales of $2-3 billion for NT1 alone, with Takeda's broader orexin agonist portfolio potentially more than doubling that revenue across multiple indications.
Strong institutional accumulation in Q2 2026: FMR LLC added 34.9%, Millennium Management and Qube Research took new positions, and BNP Paribas and Balyasny doubled their holdings.
Analyst consensus shows 14 Buy/Strong Buy ratings vs 7 Hold and 0 Sell, with a mean price target of $22.61 (implied upside from the $19.77 current price).
▼ Bear Case6
DEA scheduling still pending; the FDA approval letter states scheduling under the Controlled Substances Act is not yet complete, and Orzeyful cannot be dispensed until the DEA publishes a scheduling notice, expected by November 2026.
Label is limited to narcolepsy type 1 (NT1) in adults only, excluding the larger narcolepsy type 2 population and children, limiting the addressable market.
Takeda is a large diversified pharma; Orzeyful is a small part of a broad portfolio, so even blockbuster sales would have modest impact on the overall stock.
Multiple insiders sold shares around the August 2026 approval, including the CEO and President of R&D, totaling over $2M in disclosed sales.
Competition from established narcolepsy therapies (Xywav, Xyrem, solriamfetol) and a wave of future orexin agonists from other developers could pressure market share.
Side effects include insomnia, increased urinary frequency, and potential for abuse, which may limit adoption.

Upcoming Catalysts

  • DEA scheduling decision expected by November 2026 for US commercial availability
  • Takeda Capital Markets Day on December 11, 2026 with peak-sales targets
  • Q3 fiscal 2026 earnings and brand growth

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 11

Hover a chip for the title
1 takeda.com2 fda.gov3 drugs.com4 takeda.com5 takeda.com6 biospace.com7 nature.foleon.com8 takeda.com9 accessdata.fda.gov10 nejm.org11 trialfriend.com